Bortezomib is a proteasome inhibitor used in multiple myeloma and mantle cell lymphoma treatment.
It disrupts protein degradation pathways, causing apoptosis in cancer cells by preventing the breakdown of pro-apoptotic proteins.
Other drugs listed function via alternative mechanisms, not proteasome inhibition.